From a pool of the 52-week trial and seven 12-week trials: Local injection site reactions occurred in 3.2% and 3.0% of Repatha®-treated and placebo-treated patients, respectively. The most common ...
THOUSAND OAKS, Calif., Aug. 25, 2025 /PRNewswire/ -- Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has broadened the approved use of Repatha® (evolocumab) to ...
Most Medicare drug plans cover Repatha (evolocumab). This includes stand-alone Part D prescription drug plans and Medicare Advantage plans that include prescription drug coverage. Doctors prescribe ...
AbbVie’s Qulipta (atogepant tablets) has been approved for the preventive treatment of episodic migraine in adults. In the pivotal Phase 3, multicenter, randomized, double-blind, placebo-controlled, ...
As Amgen strives to become the industry’s top player in cardiometabolic risk reduction by the start of the next decade, the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results